PC-ART-005 Reference 22 August 2026 7 min read

The workplace panel is a closed list

Start with the tightest fact available, because it is unusually clean. The federally mandated urine panel in the United States contains five analytes with published cutoff concentrations: marijuana metabolite, cocaine metabolite, opioids, phencyclidine and amphetamines. A closed list of five. No peptide appears on it, and the immunoassays are calibrated to those named targets, with cross-reactivity specified only within a drug class.

That is a fact about a list, and it is worth knowing exactly how far it carries. Benzodiazepines are not on the mandated panel, though they get named as though they were. Expanded panels used by private employers vary and are not governed by the federal guidelines. And "no peptide is an analyte" describes what the panel looks for — it is not a demonstration that nothing would ever be seen. No cited document tests that, so the absolute version of the claim is unsourced.

There is a framing point underneath all of this worth saying out loud. The reason this fact usually gets published is to reassure somebody that a substance will not be found. That is a different job from describing a testing regime, and the two are very easy to confuse.

What anti-doping laboratories actually run

Anti-doping laboratories are a different world, and a genuinely impressive one. Liquid chromatography coupled to mass spectrometry is the mandated platform for the small-peptide classes, and high-resolution screening for peptide hormones has been funded and built specifically for this job. The platform is not uniform across the whole field, though, and the exception lands squarely on the growth hormone axis: the two tests for growth hormone itself are immunoassay-based — an isoform differential immunoassay, and a biomarkers test measuring IGF-1 and the N-terminal propeptide of type III collagen.

The sensitivity figures in circulation are a step more aggressive than the rules require. Minimum required performance levels are published in a technical document, and for the relevant classes they sit at or above 1 ng/mL — growth hormone releasing peptides at 1 ng/mL, secretagogues and mimetics in the same region. Sub-nanogram detection describes what some instruments can do, not the harmonised level laboratories must meet.

Two classification facts finish the picture, and both are usually stated backwards. BPC-157 sits in class S0, non-approved substances, which sweeps up any pharmacological substance not addressed elsewhere on the list and not currently approved for human therapeutic use. Growth hormone secretagogues, GHRH analogues and TB-500 sit in class S2, peptide hormones and growth factors. S0 substances are Specified Substances and S2 substances are not — the reverse of the usual assumption that S0 is the harsher box.

Detection windows are not half-lives

This is the good bit, and it is where most published tables fall apart. A plasma half-life describes how fast a compound leaves the circulation. A urinary detection window describes how long a laboratory can still find something in urine. Different quantities, and reading one off the other is the single most common error on this subject. A long half-life can even work against urinary detection — an albumin-bound peptide is held in circulation, which is a reason it is not filtered into urine.

Follow the real urinary numbers for the growth hormone releasing peptides back and they all land in one place, whose design bounds everything that can be said from it. In that study GHRP-6 was mostly excreted unchanged and detected 23 hours after administration; the longest figure for any compound in it was 47 hours, for GHRP-2. Ipamorelin was extensively metabolised and excreted as parent plus metabolites, with the 1–4 free acid still detectable after the parent had gone — so a metabolite extends the window, and the parent is detected too.

Three qualifications travel with those numbers and get dropped every single time. Administration was nasal, not injected, which is not how these compounds are used. Collection ran for a limited period, so the longest figure is censored by the study rather than by the biology. And these are single-volunteer excretion results, which means they are not averages of anything — they are one person's result each.

For BPC-157 there is no human urinary figure at all. The nearest real numbers are animal: intact peptide is undetectable in rat and dog plasma beyond about four hours, and 15.9 to 17.8% of a dose is recovered in rat urine over 72 hours. Any four-day human window quoted for it is an extrapolation across species, and nothing published supports the metabolites-linger-for-weeks story for any of these compounds.

• Presence is the violation

  Under the anti-doping code, the presence of a prohibited substance in a sample is itself a rule violation, without proof of intent, fault, negligence or knowing use. This applies to every class on the list, not to one of them.

• A therapeutic exemption is not barred

  The international standard applies one set of four conditions to any prohibited substance, and there is no carve-out excluding a class from applying. What makes an exemption unrealistic for a research compound is that the criteria require a diagnosed condition and an indicated treatment — not a categorical bar.

• Sanctions differ by body

  A first collegiate positive for a banned drug other than narcotics carries 365 days of ineligibility and the loss of one season, not a multi-year ban. Multi-year outcomes arise under other codes and for other circumstances.

What changes a window, and what is asserted to

Two things genuinely move a detection window, and the rest is confident invention. Dose and frequency shift it arithmetically: a higher starting concentration takes more half-lives to fall below a threshold. That needs no study, it is just arithmetic. Route matters too, and the literature says so in general terms.

Past that point the specifics run out. No published head-to-head study compares subcutaneous with intravenous excretion for these peptides, so the familiar claim that subcutaneous injection lengthens the tail is an assertion. There is no evidence for the chain running from training load or dehydration through impaired clearance to a longer window — impaired clearance prolonging elimination is a general principle, and the specific version has not been tested here. And no saturation study exists for any of these compounds, so tissue saturation from a loading phase is a mechanism nobody has measured.

The honest summary is short, and more useful than a table. A published detection window is a figure from a small study under one route, and for several of these compounds no human figure exists.

Minimum required performance level

The concentration at which an anti-doping laboratory must be able to detect a non-threshold substance, set by technical document. For the peptide classes here it is at or above 1 ng/mL.

S0

Non-approved substances: any pharmacological substance not addressed by another section of the prohibited list and not currently approved for human therapeutic use. BPC-157 is named in it.

S2

Peptide hormones, growth factors and related substances, covering growth hormone secretagogues, GHRH analogues and TB-500.

Strict liability

The principle that presence of a prohibited substance in a sample is a violation without proof of intent or fault. It attaches to presence, not to a particular class.

DAC

Drug affinity complex, a modification that binds a peptide to serum albumin. It extends the half-life and the duration of effect; its effect on urinary detectability is not established.

Detection window

How long a laboratory can still find a substance or its metabolites in a sample. A different quantity from a plasma half-life and not derivable from one.

Sources and evidence